There are three phase III clinical studies in VV 1 16, and the completed phase III clinical study is head-to-head, that is, the control is a positive control drug, but the drug supervision department still wants to see more data, including a placebo. In two ongoing phase III clinical studies, both were controlled placebos.
A phase III clinical study of Junshi Bio-oral nucleoside anti-novel coronavirus (novel coronavirus) drug vv11(JT001) was published in the New England Journal of Medicine in the early morning of February 29th, 2022.
Brief introduction of Shi Jun's biology
Junshi Bio was founded in 20 12 and 12. It is an innovation-driven biopharmaceutical company, dedicated to the discovery and development of innovative drugs, as well as clinical research and development and commercialization on a global scale. The business scope includes biomedical research and development, and provides related technology development and technical consultation.
Junshi Bio is in a leading position in the fields of tumor immunotherapy, autoimmune diseases and metabolic diseases treatment by virtue of its excellent innovative drug discovery ability, advanced biotechnology research and development, large-scale production technology in the whole industry chain and rapid expansion of the drug combination under research with huge market potential.
Reference to the above content: Baidu Encyclopedia-Shanghai Junshi Biomedical Technology Co., Ltd.